TY - JOUR TI - A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19 AU - Chen J AU - Liu D AU - Liu L AU - Liu P AU - Xu Q AU - Xia L AU - Ling Y AU - Huang D AU - Song S AU - Zhang D AU - Qian Z AU - Li T AU - Shen Y AU - Lu H AB - OBJECTIVE: To evaluate the efficacy and safety of hydroxychloroquine (HCQ) in the treatment of patients with moderate coronavirus disease 2019 (COVID-19). METHODS: We prospectively enrolled 30 treatment-naïve patients with confirmed COVID-19 after informed consent at Shanghai Public Health Clinical Center. The patients were randomized 1:1 to HCQ group and the control group. Patients in HCQ group were given HCQ 400 mg per day for 5 days plus conventional treatments, while those in the control group were given conventional treatment only. The primary endpoint was negative conversion rate of SARS-CoV-2 nucleic acid in respiratory pharyngeal swab on days 7 after randomization. This study has been approved by the Ethics Committee of Shanghai Public Health Clinical Center and registered online (NCT04261517). RESULTS: One patient in HCQ group developed to severe during the treatment. On day 7, nucleic acid of throat swabs was negative in 13 (86.7%) cases in the HCQ group and 14 (93.3%) cases in the control group (P>0.05). The median duration from hospitalization to virus nucleic acid negative conservation was 4 (1,9) days in HCQ group, which is comparable to that in the control group [2 (1,4) days, Z=1.27, P>0.05]. The median time for body temperature normalization in HCQ group was 1 (0,2) day after hospitalization, which was also comparable to that in the control group [1 (0,3) day]. Radiological progression was shown on CT images in 5 cases (33.3%) of the HCQ group and 7 cases (46.7%) of the control group, and all patients showed improvement in follow-up examinations. Four cases (26.7%) of the HCQ group and 3 cases (20%) of the control group had transient diarrhea and abnormal liver function (P>0.05). CONCLUSIONS: The prognosis of COVID-19 moderate patients is good. Larger sample size study are needed to investigate the effects of HCQ in the treatment of COVID-19. Subsequent research should determine better endpoint and fully consider the feasibility of experiments such as sample size. LA - English T2 - 浙江大学学报(医学版)(Journal of Zhejiang University. Medical Sciences) VL - 49 SP - 215-219 IS - 2 SN - 1008-9292 PY - 2020 DA - 2020 DO - 10.3785/j.issn.1008-9292.2020.03.03 U1 - 32391667[pmid] DB - EPISTEMONIKOS UR - http://www.epistemonikos.org/documents/30d0f2552ff5342fbfcd1b09e9bac66d1325b467 ER -